FGF1 and Cholestatic liver disease: Secondly, the ANIT-induced intrahepatic cholestaisis mouse model used in the present study only depicts certain aspects of cholestatic liver disease, extra experimental models are also required to evaluate the potentially therapeutic value of FGF1 mutants.